Advertisement
Singapore markets closed

  • Straits Times Index

    3,313.48
    +8.49 (+0.26%)
     

  • Nikkei

    38,787.38
    -132.88 (-0.34%)
     

  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     

  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     

  • Bitcoin USD

    66,745.76
    +1,517.24 (+2.33%)
     

  • CMC Crypto 200

    1,364.63
    -9.22 (-0.67%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • Dow

    40,003.59
    +134.21 (+0.34%)
     

  • Nasdaq

    16,685.97
    -12.35 (-0.07%)
     

  • Gold

    2,419.80
    +34.30 (+1.44%)
     

  • Crude Oil

    80.00
    +0.77 (+0.97%)
     

  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     

  • FTSE Bursa Malaysia

    1,616.62
    +5.51 (+0.34%)
     

  • Jakarta Composite Index

    7,317.24
    +70.54 (+0.97%)
     

  • PSE Index

    6,618.69
    -9.51 (-0.14%)
     

I-MAB Filed 2023 Annual Report on Form 20-F

PR Newswire
·1-min read

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.

(PRNewsfoto/I-Mab Biopharma)
(PRNewsfoto/I-Mab Biopharma)

The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, 2440 Research Blvd., Suite 400, Rockville, MD, 20850.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.

ADVERTISEMENT

I-Mab Contacts

Investors & Media

Tyler Ehler

Senior Director, Investor Relations

IR@i-mabbiopharma.com

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2023-annual-report-on-form-20-f-302130508.html

SOURCE I-Mab Biopharma